| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on debt extinguishment | NaN | 0 | 0 | 0 |
| Unrealized (gain) loss from transactions denominated in a foreign currency | NaN | NaN | 12 | -26 |
| Realized loss on equity investments | NaN | NaN | 0 | 0 |
| Realized/unrealized loss (gain) on equity investments | NaN | 0 | NaN | NaN |
| Change in fair value of equity warrants issued by licensee | NaN | 0 | 0 | 0 |
| Depreciation | NaN | NaN | NaN | 433 |
| Net loss | -6,967 | -8,373 | -12,585 | -45,460 |
| Depreciation | 197 | 202 | 253 | 400 |
| Amortization of intangible assets | NaN | NaN | NaN | 500 |
| Amortization of intangible assets | 240 | 241 | 240 | 480 |
| Amortization of debt-related costs | 159 | 156 | 152 | 285 |
| Stock-based compensation | 11,967 | 14,314 | 12,243 | 15,163 |
| Non-cash lease expense | 77 | 154 | 205 | 323 |
| Net amortization/accretion of marketable securities | 849 | 925 | 1,534 | 3,023 |
| Accounts receivable, net | 30,287 | 12,437 | 14,286 | 11,574 |
| Inventory | 196 | 536 | -37 | 1,252 |
| Other receivables | -189 | 336 | -190 | 608 |
| Other long-term liabilities | NaN | 0 | 0 | 0 |
| Prepaid expenses | 13,244 | -8,187 | -7,978 | 14,449 |
| Other non-current assets | -141 | 381 | 373 | -227 |
| Accounts payable | 7,714 | -30,539 | 23,842 | 13,603 |
| Accrued payroll and benefits | -9,250 | 4,228 | 1,940 | -4,212 |
| Other accrued liabilities | 15,457 | 45,389 | NaN | NaN |
| Net cash used in operating activities | -24,652 | 19,330 | 18,257 | -50,038 |
| Purchases of long-term investments | NaN | 870 | 0 | 0 |
| Proceeds from maturities of marketable securities | 74,055 | 92,082 | 99,500 | 170,218 |
| Intangible asset additions | NaN | 0 | NaN | NaN |
| Purchases of marketable securities | 126,799 | 35,580 | 102,333 | 255,273 |
| Purchases of property and equipment | 5,818 | 6,358 | 1,910 | 1,591 |
| Net cash used in investing activities | -58,562 | 49,274 | -4,743 | -86,646 |
| Proceeds from issuance of common stock, net of paid issuance costs-Common Stock | NaN | 134,771 | NaN | NaN |
| Proceeds from issuance of pre-funded warrants, net of paid issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from sale of common stock under employee stock purchase plan | NaN | 1,236 | 0 | 1,101 |
| Proceeds from issuance of common stock, net of paid issuance costs-A2023ATMProspectus | NaN | 0 | NaN | NaN |
| Proceeds from long-term debt | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock, net of paid issuance costs | -134,771 | NaN | 0 | 134,771 |
| Payment of debt issuance costs | NaN | 0 | 0 | 0 |
| Payments for debt extinguishment | NaN | 0 | 0 | 0 |
| Proceeds from exercise of stock options | 1,204 | 1,076 | 2,562 | 2,642 |
| Net cash provided by financing activities | 1,204 | 2,312 | 2,562 | 138,514 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -82,010 | 70,916 | 16,076 | 1,830 |
| Cash, cash equivalents and restricted cash at beginning of period | 186,203 | 115,287 | 97,381 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 104,193 | 186,203 | 115,287 | NaN |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)